Symbols / GTBP $0.45 -1.00% GT Biopharma, Inc.
GTBP Chart
About
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 14.04M |
| Enterprise Value | 7.37M | Income | -34.45M | Sales | — |
| Book/sh | 0.23 | Cash/sh | 0.22 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1 | IPO | — |
| P/E | — | Forward P/E | -0.04 | PEG | — |
| P/S | — | P/B | 1.96 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 2.94 |
| Current Ratio | 3.50 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -6.68 | EPS next Y | -10.80 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-02 07:00 | ROA | -125.85% |
| ROE | -13.77% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 31.55M |
| Shs Float | 30.83M | Short Float | 3.23% | Short Ratio | 1.30 |
| Short Interest | — | 52W High | 3.85 | 52W Low | 0.39 |
| Beta | 1.20 | Avg Volume | 1.13M | Volume | 339.04K |
| Target Price | $3.00 | Recom | None | Prev Close | $0.45 |
| Price | $0.45 | Change | -1.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.00
Mean price target
2. Current target
$0.45
Latest analyst target
3. DCF / Fair value
$-6.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.45
Low
$3.00
High
$3.00
Mean
$3.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-12-02 | init | Roth MKM | — → Buy | $11 |
- Should I buy GT Biopharma (GTBP) - Zacks Investment Research hu, 12 Mar 2026 07
- If You Invested $1,000 in Gt Biopharma Inc (GTBP) - Stock Titan Mon, 23 Mar 2026 06
- GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance Mon, 16 Mar 2026 07
- Cancer trial firm GT Biopharma says $9M cash funds work into late 2026 - Stock Titan Mon, 02 Mar 2026 08
- GT Biopharma (GTBP) price target decreased by 62.50% to 3.06 - MSN Sun, 29 Mar 2026 11
- GT Biopharma Reports Successful Phase 1 Trial Progress for GTB-3650 in Hematologic Malignancies - Quiver Quantitative Wed, 08 Oct 2025 07
- GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance hu, 12 Mar 2026 07
- GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally - Stocktwits hu, 09 Oct 2025 02
- What date does GT Biopharma's (GTBP) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research hu, 12 Mar 2026 07
- GT Biopharma Reports Full Year 2025 Financial Results - GlobeNewswire Mon, 02 Mar 2026 08
- GTBP Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI Wed, 14 May 2025 05
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 22
- GTBP SEC Filings - Gt Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 01 Apr 2026 07
- EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - Yahoo Finance Wed, 08 Oct 2025 07
- Immuno-oncology GT Biopharma to detail TriKE platform for Toronto investors - Stock Titan ue, 17 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
12.42
-13.52%
|
14.36
+5.80%
|
13.58
-36.13%
|
21.26
|
| Research And Development |
|
3.47
-40.12%
|
5.80
-10.33%
|
6.47
-26.61%
|
8.81
|
| Selling General And Administration |
|
8.95
+4.48%
|
8.57
+20.48%
|
7.11
-42.87%
|
12.45
|
| General And Administrative Expense |
|
—
|
—
|
—
|
—
|
| Other Gand A |
|
—
|
—
|
—
|
—
|
| Total Expenses |
|
12.42
-13.52%
|
14.36
+5.80%
|
13.58
-36.13%
|
21.26
|
| Operating Income |
|
-12.42
+13.52%
|
-14.36
-5.80%
|
-13.58
+36.13%
|
-21.26
|
| Total Operating Income As Reported |
|
-12.42
+13.52%
|
-14.36
-5.80%
|
-13.58
+36.13%
|
-21.26
|
| EBITDA |
|
-28.23
-114.46%
|
-13.16
-78.25%
|
-7.38
+64.63%
|
-20.88
|
| Normalized EBITDA |
|
-0.73
+94.77%
|
-13.96
-9.28%
|
-12.78
+39.06%
|
-20.96
|
| EBIT |
|
-28.23
-114.46%
|
-13.16
-78.25%
|
-7.38
+64.63%
|
-20.88
|
| Total Unusual Items |
|
-27.50
-3537.13%
|
0.80
-85.16%
|
5.39
+5958.43%
|
0.09
|
| Total Unusual Items Excluding Goodwill |
|
-27.50
-3537.13%
|
0.80
-85.16%
|
5.39
+5958.43%
|
0.09
|
| Special Income Charges |
|
-27.74
|
0.00
-100.00%
|
0.55
|
0.00
|
| Other Special Charges |
|
27.74
|
—
|
-0.55
|
—
|
| Net Income |
|
-28.35
-115.42%
|
-13.16
-73.25%
|
-7.60
+63.62%
|
-20.88
|
| Pretax Income |
|
-28.35
-115.42%
|
-13.16
-73.25%
|
-7.60
+63.62%
|
-20.88
|
| Net Non Operating Interest Income Expense |
|
-0.00
-101.00%
|
0.40
-29.10%
|
0.57
+99.65%
|
0.28
|
| Interest Expense Non Operating |
|
0.13
|
0.00
-100.00%
|
0.21
+2562.50%
|
0.01
|
| Net Interest Income |
|
-0.00
-101.00%
|
0.40
-29.10%
|
0.57
+99.65%
|
0.28
|
| Interest Expense |
|
0.13
|
0.00
-100.00%
|
0.21
+2562.50%
|
0.01
|
| Interest Income Non Operating |
|
0.12
-69.40%
|
0.40
-48.46%
|
0.78
+167.12%
|
0.29
|
| Interest Income |
|
0.12
-69.40%
|
0.40
-48.46%
|
0.78
+167.12%
|
0.29
|
| Other Income Expense |
|
-15.93
-2091.00%
|
0.80
-85.22%
|
5.41
+5980.90%
|
0.09
|
| Other Non Operating Income Expenses |
|
11.57
|
—
|
0.02
|
—
|
| Gain On Sale Of Security |
|
0.24
-69.88%
|
0.80
-83.49%
|
4.84
+5343.82%
|
0.09
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-28.35
-115.42%
|
-13.16
-73.25%
|
-7.60
+63.62%
|
-20.88
|
| Net Income From Continuing Operation Net Minority Interest |
|
-28.35
-115.42%
|
-13.16
-73.25%
|
-7.60
+63.62%
|
-20.88
|
| Net Income From Continuing And Discontinued Operation |
|
-28.35
-115.42%
|
-13.16
-73.25%
|
-7.60
+63.62%
|
-20.88
|
| Net Income Continuous Operations |
|
-28.35
-115.42%
|
-13.16
-73.25%
|
-7.60
+63.62%
|
-20.88
|
| Normalized Income |
|
-0.86
+93.86%
|
-13.96
-7.49%
|
-12.99
+38.07%
|
-20.97
|
| Net Income Common Stockholders |
|
-34.45
-161.73%
|
-13.16
-73.25%
|
-7.60
+63.62%
|
-20.88
|
| Otherunder Preferred Stock Dividend |
|
5.78
|
0.00
|
—
|
—
|
| Diluted EPS |
|
—
|
-6.94
-23.05%
|
-5.64
+71.02%
|
-19.46
|
| Basic EPS |
|
—
|
-6.94
-23.05%
|
-5.64
+71.02%
|
-19.46
|
| Basic Average Shares |
|
—
|
1.90
+40.78%
|
1.35
+25.60%
|
1.07
|
| Diluted Average Shares |
|
—
|
1.90
+40.78%
|
1.35
+25.60%
|
1.07
|
| Diluted NI Availto Com Stockholders |
|
-34.45
-161.73%
|
-13.16
-73.25%
|
-7.60
+63.62%
|
-20.88
|
| Preferred Stock Dividends |
|
0.32
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
8.11
+91.54%
|
4.23
-70.00%
|
14.11
-15.70%
|
16.74
|
| Current Assets |
|
8.11
+91.54%
|
4.23
-69.89%
|
14.06
-15.13%
|
16.56
|
| Cash Cash Equivalents And Short Term Investments |
|
6.81
+72.39%
|
3.95
-71.72%
|
13.97
-15.36%
|
16.51
|
| Cash And Cash Equivalents |
|
6.81
+72.39%
|
3.95
+266.17%
|
1.08
-80.98%
|
5.67
|
| Other Short Term Investments |
|
—
|
0.00
-100.00%
|
12.89
+18.98%
|
10.84
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Current Deferred Assets |
|
0.63
|
0.00
|
—
|
—
|
| Restricted Cash |
|
0.09
+1.08%
|
0.09
|
0.00
|
—
|
| Other Current Assets |
|
0.57
+201.60%
|
0.19
+123.81%
|
0.08
+55.56%
|
0.05
|
| Total Non Current Assets |
|
0.00
|
0.00
-100.00%
|
0.05
-69.54%
|
0.17
|
| Net PPE |
|
—
|
0.00
-100.00%
|
0.05
-67.88%
|
0.17
|
| Gross PPE |
|
—
|
0.00
-100.00%
|
0.05
-67.88%
|
0.17
|
| Other Properties |
|
—
|
—
|
0.05
-67.88%
|
0.17
|
| Non Current Prepaid Assets |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Total Liabilities Net Minority Interest |
|
2.32
-60.71%
|
5.90
-11.02%
|
6.63
+32.61%
|
5.00
|
| Current Liabilities |
|
2.32
-60.71%
|
5.90
-11.02%
|
6.63
+34.33%
|
4.94
|
| Payables And Accrued Expenses |
|
2.31
-59.15%
|
5.65
+2.30%
|
5.52
+14.85%
|
4.81
|
| Payables |
|
0.75
-80.59%
|
3.85
-10.98%
|
4.33
+37.83%
|
3.14
|
| Accounts Payable |
|
0.75
-80.59%
|
3.85
-10.98%
|
4.33
+37.83%
|
3.14
|
| Current Accrued Expenses |
|
1.56
-13.19%
|
1.80
+50.38%
|
1.20
-28.40%
|
1.67
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.06
-47.27%
|
0.11
|
| Current Debt |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.06
-47.27%
|
0.11
|
| Other Current Liabilities |
|
0.01
-95.63%
|
0.25
-76.05%
|
1.05
+5436.84%
|
0.02
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.06
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.06
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.06
|
| Stockholders Equity |
|
5.79
+446.53%
|
-1.67
-122.34%
|
7.48
-36.29%
|
11.73
|
| Common Stock Equity |
|
5.79
+446.26%
|
-1.67
-122.35%
|
7.47
-36.29%
|
11.73
|
| Capital Stock |
|
0.03
+800.00%
|
0.00
+50.00%
|
0.00
-94.12%
|
0.03
|
| Common Stock |
|
0.03
+1200.00%
|
0.00
+100.00%
|
0.00
-96.97%
|
0.03
|
| Preferred Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Share Issued |
|
25.53
+1042.81%
|
2.23
+61.83%
|
1.38
+26.58%
|
1.09
|
| Ordinary Shares Number |
|
25.53
+1042.81%
|
2.23
+61.83%
|
1.38
+26.58%
|
1.09
|
| Additional Paid In Capital |
|
729.66
+5.21%
|
693.55
+0.58%
|
689.54
+0.49%
|
686.17
|
| Retained Earnings |
|
-723.90
-4.12%
|
-695.23
-1.93%
|
-682.07
-1.13%
|
-674.47
|
| Total Equity Gross Minority Interest |
|
5.79
+446.53%
|
-1.67
-122.34%
|
7.48
-36.29%
|
11.73
|
| Total Capitalization |
|
5.79
+446.53%
|
-1.67
-122.34%
|
7.48
-36.29%
|
11.73
|
| Working Capital |
|
5.79
+446.53%
|
-1.67
-122.50%
|
7.42
-36.14%
|
11.62
|
| Invested Capital |
|
5.79
+446.26%
|
-1.67
-122.35%
|
7.47
-36.29%
|
11.73
|
| Total Debt |
|
—
|
0.00
-100.00%
|
0.06
-66.67%
|
0.17
|
| Capital Lease Obligations |
|
—
|
0.00
-100.00%
|
0.06
-66.67%
|
0.17
|
| Net Tangible Assets |
|
5.79
+446.53%
|
-1.67
-122.34%
|
7.48
-36.29%
|
11.73
|
| Tangible Book Value |
|
5.79
+446.26%
|
-1.67
-122.35%
|
7.47
-36.29%
|
11.73
|
| Interest Payable |
|
—
|
—
|
—
|
—
|
| Line Of Credit |
|
—
|
—
|
—
|
0.00
|
| Preferred Shares Number |
|
0.12
+0.00%
|
0.12
+0.00%
|
0.12
+0.00%
|
0.12
|
| Preferred Stock Equity |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-12.91
-0.08%
|
-12.90
-45.77%
|
-8.85
+41.83%
|
-15.22
|
| Cash Flow From Continuing Operating Activities |
|
-12.91
-0.08%
|
-12.90
-45.77%
|
-8.85
+41.83%
|
-15.22
|
| Net Income From Continuing Operations |
|
-28.35
-115.42%
|
-13.16
-73.25%
|
-7.60
+63.62%
|
-20.88
|
| Other Non Cash Items |
|
17.32
|
—
|
0.11
-13.85%
|
0.13
|
| Stock Based Compensation |
|
0.43
+87.83%
|
0.23
-89.55%
|
2.20
-71.23%
|
7.65
|
| Operating Gains Losses |
|
-1.40
-74.38%
|
-0.80
+85.03%
|
-5.34
-3462.67%
|
-0.15
|
| Gain Loss On Investment Securities |
|
-0.20
+75.38%
|
-0.80
+83.32%
|
-4.80
-3931.09%
|
-0.12
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
0.00
+100.00%
|
-0.05
-260.00%
|
0.03
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.11
+17.89%
|
0.10
|
| Change In Working Capital |
|
-0.92
-211.11%
|
0.83
-57.25%
|
1.94
+197.39%
|
-1.99
|
| Change In Prepaid Assets |
|
0.38
+462.50%
|
-0.10
-395.24%
|
-0.02
-116.54%
|
0.13
|
| Change In Payables And Accrued Expense |
|
-1.30
-238.42%
|
0.94
-52.24%
|
1.96
+196.65%
|
-2.03
|
| Change In Accrued Expense |
|
—
|
—
|
—
|
0.00
|
| Change In Payable |
|
—
|
—
|
—
|
-2.03
|
| Change In Account Payable |
|
—
|
—
|
—
|
-2.03
|
| Change In Other Current Assets |
|
0.00
-100.00%
|
0.05
-52.68%
|
0.11
+17.89%
|
0.10
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.06
+50.00%
|
-0.12
-34.88%
|
-0.09
|
| Investing Cash Flow |
|
0.00
-100.00%
|
12.89
+741.76%
|
-2.01
-116.54%
|
12.14
|
| Cash Flow From Continuing Investing Activities |
|
0.00
-100.00%
|
12.89
+741.76%
|
-2.01
-116.54%
|
12.14
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
12.89
+741.76%
|
-2.01
-116.54%
|
12.14
|
| Purchase Of Investment |
|
—
|
—
|
—
|
—
|
| Sale Of Investment |
|
0.00
-100.00%
|
12.89
|
—
|
—
|
| Financing Cash Flow |
|
15.78
+430.07%
|
2.98
-52.52%
|
6.27
+2898.21%
|
-0.22
|
| Cash Flow From Continuing Financing Activities |
|
15.78
+430.07%
|
2.98
-52.52%
|
6.27
+2898.21%
|
-0.22
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
2.98
-52.52%
|
6.27
+2898.21%
|
-0.22
|
| Common Stock Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.22
|
| Cash Dividends Paid |
|
-0.23
|
0.00
|
—
|
—
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
+100.00%
|
-0.22
|
| Proceeds From Stock Option Exercised |
|
5.50
|
0.00
|
—
|
0.00
|
| Changes In Cash |
|
2.86
-3.51%
|
2.96
+164.55%
|
-4.59
-39.35%
|
-3.30
|
| Beginning Cash Position |
|
4.04
+274.79%
|
1.08
-80.98%
|
5.67
-36.75%
|
8.97
|
| End Cash Position |
|
6.91
+70.75%
|
4.04
+274.79%
|
1.08
-80.98%
|
5.67
|
| Free Cash Flow |
|
-12.91
-0.08%
|
-12.90
-45.77%
|
-8.85
+41.83%
|
-15.22
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
-100.00%
|
0.21
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Change In Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Common Stock Issuance |
|
0.00
-100.00%
|
2.98
-52.52%
|
6.27
|
0.00
|
| Issuance Of Capital Stock |
|
10.51
+253.09%
|
2.98
-52.52%
|
6.27
|
0.00
|
| Net Preferred Stock Issuance |
|
10.51
|
—
|
—
|
—
|
| Preferred Stock Dividend Paid |
|
-0.23
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
10.51
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-02 View
- 8-K2026-03-02 View
- 8-K2025-11-26 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 8-K2025-09-26 View
- 8-K2025-09-23 View
- 42025-09-08 View
- 42025-09-08 View
- 42025-09-08 View
- 42025-09-08 View
- 42025-09-08 View
- 8-K2025-08-29 View
- 10-Q2025-08-14 View
- 8-K2025-07-24 View
- 8-K2025-06-11 View
- 8-K2025-05-27 View
- 10-Q2025-05-15 View
- 8-K2025-05-13 View
- 8-K2025-05-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|